Day 2 2023 - *Subject to change* - CET/CEST (Cent Europe Summer, GMT+2)
Day 2 2023 - *Subject to change* - CET/CEST (Cent Europe Summer, GMT+2)
This session dives into the ever-evolving landscape of dealmaking and unravels the forces reshaping the industry's dynamics. Hear real-world case studies and expert insights on strategies for forging strategic alliances, securing partnerships, and driving innovation, to address the healthcare challenges of the future. Whether you're a pharmaceutical executive, investor, or innovator, this session navigates the intricacies of dealmaking and provides guidance for success, in this transformative era
This session will focus on the process and complexities of real-life deals made via strategic partnerships. It will unravel the interplay of scientific expertise, intellectual property (IP), due diligence, legal and regulatory requirements, financial considerations and negotiation. Ultimately, it will portray how the various factors either lead to the downfall or success of a deal, impacting innovation and the commercialisation of a novel product, beneficial to patients in need.
In this session, the panelists will explore the latest trends and developments in oncology. They will also share insights on successful deal-making in the space, with a particular focus on the creating effective partnerships between the (small) biotech players and pharma heavyweights (companies)
This session delves into the landscape of Cell and Gene Therapy (C>) with a focus on its current status and emerging trends. Experts will share valuable insights into the opportunities and challenges confronting C>, shedding light on its promising potential. The discussion will also spotlight the legislative and procedural aspects involved in bringing C> innovations to market, with emphasis on Europe. Ultimately, this session aims to ensure accessibility for those in need, while shaping the future of the life science industry.
This session will explore the rise in close collaborations between CROs and other Service Providers with the Venture Capital and Fundraising/Partnering community. The panel will discuss how biotech's are benefitting from these collaborations through: better early engagement, development planning, scientific and therapeutic advice, and budget forecasting. Finally, we will discuss how these collaborations are helping biotech's achieve their fundraising and partnering goals.
- Brandon Early - Vice President Project Delivery, ICON plc
- Fabian Berkemeier - Managing Director, IGES Institute
- Kevin Rieger - Director Corporate Affairs Germany, BeiGene
- Benjamin Minow - Managing Director, WuXi Biologics Germany
This ever-popular session takes a deep dive into the current state of the life sciences industry with the expertise of today’s leading pharma dealmakers. Join this engaging discussion to learn how to navigate the current turbulent waters of the biotech industry.
In today's dynamic pharmaceutical landscape, optimizing asset utilization is pivotal for sustained growth and innovation. This session explores how pharmaceutical companies can create substantial value by externalizing deprioritized assets to biotech partners and actively participating in the innovation ecosystem. We delve into the transformative power of data mining, asset repositioning, and the strategic integration of Artificial Intelligence (AI) in out-licensing activities. Join us as we navigate the evolving landscape of pharma-biotech collaborations, unveiling new avenues for generating value, fostering innovation, and reshaping the future of healthcare.
- Peter Dolan, Ph.D., J.D. - Director, Global Out-Licesning, Sanofi
Translational Funds represent an exciting development in the European venture capital landscape, as they provide a unique funding and support mechanism for startups at the intersection of science and entrepreneurship
As the new era begins to redefine the structure of fundraising, a stronger relationship between the pharmaceutical industry and early-stage investors has formed. Join this session to discover the dynamic between the pharmaceutical cooperate venture arms and investors, the benefits that the partnership offers, and how it proves to be an effective strategy for pharma to tap into early-stage companies which are driving innovation in the life sciences ecosystem.
- Brad Robling - Vice President Lilly New Ventures, Eli Lilly and Company
- Christian Stiebner - Senior Investment Manager, KfW Capital
- Stefan Fischer - Managing Partner, TVM Capital Life Science
Join us for a conversation between VC industry veterans and emerging VCs about the pitfalls in biotech, the lessons learnt and how to stay passionate, followed by drinks.
- Jan Wauters - Science & Technology Counselor, Flanders Investment & Trade
- Urmi Prasad Richardson - President EMEA, Thermo Fisher Scientific
- Jiao Peng - CEO, BiBo Pharma
During this session, panelists will discuss the essential ingredients that need to be brought to the table, from both sides, to cook together and form a partnership/ successful collaboration.
- Juliette Lemaigne - Partner, Foundation Inartis
- Regina Hodits - Managing Partner, Wellington Partners
- Peter Nell - Co-founder and CEO, Stealthmode Company
- Ben Panter - Founder & CEO, Blackford Analysis
- Isabelle Scarabin - Director, Business Development & Licensing Officer, Bayer
- Jan-Philipp Kruse - Senior Director BD&L & OI - Lead Bayer Co.Lab, Bayer Pharmaceuticals
- Jörg Knaebelein - Scientific Finder Collaborate to Cure Hub EMEA, Bayer Pharmaceuticals
- Christoph Broja - Managing Director, EQT Life Sciences
- Carolin Clement - Head of Unit Biotech and Pharma, Berlin Partner for Business and Technology
13:00 – 13:15 Accession Therapeutics Limited
13:15 – 13:30 Aptevo Therapeutics Inc.
13:30 – 13:45 Elpiscience Biopharma
13:45 – 14:00 Epsilogen
14:00 – 14:15 QBiotics
14:30 – 14:45 Accelerated Biosciences Corp.
14:45 – 15:00 ENCell Co., Ltd.
16:15 – 16:30 Immunis Inc.
16:30 – 16:45 Lumosa Therapeutics
16:45 – 17:00 Genprex, Inc.
17:00 – 17:15 Regend Therapeutics